Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06186648
What this trial is testing

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

Who this might be right for
Richter Syndrome
French Innovative Leukemia Organisation 40
Testing effectiveness (Phase 2)Study completedNCT04703686
What this trial is testing

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Who this might be right for
Diffuse Large B-Cell Lymphoma RefractoryRefractory Indolent Adult Non-Hodgkin LymphomaRefractory Transformed B-cell Non-Hodgkin Lymphoma+2 more
The Lymphoma Academic Research Organisation 67
Testing effectiveness (Phase 2)Looking for participantsNCT06814496
What this trial is testing

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Who this might be right for
MelanomaMedullary Thyroid CancerSinonasal Undifferentiated Carcinoma+8 more
University of Arizona 30
Testing effectiveness (Phase 2)Looking for participantsNCT05377658
What this trial is testing

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Henan Cancer Hospital 43
Early research (Phase 1)Looking for participantsNCT07612189
What this trial is testing

NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

Who this might be right for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc. 155
Not applicableLooking for participantsNCT07609576
What this trial is testing

Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.

Who this might be right for
Lymphoma NeoplasmsMyeloma MultipleSevere Infection+3 more
Infanta Leonor University Hospital 350
Early research (Phase 1)Active Not RecruitingNCT04606472
What this trial is testing

SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 60
Early research (Phase 1)Ended earlyNCT03752177
What this trial is testing

LY3415244 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Eli Lilly and Company 12
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Large-scale testing (Phase 3)Looking for participantsNCT07010263
What this trial is testing

AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Who this might be right for
Small Cell Lung Cancer
Akeso 560
Large-scale testing (Phase 3)Active Not RecruitingNCT05587374
What this trial is testing

Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)

Who this might be right for
Nasopharyngeal CarcinomaNasopharyngeal Cancer
Sun Yat-sen University 490
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07688291
What this trial is testing

A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy

Who this might be right for
Esophageal Squamous Carcinoma Cell
Beijing GoBroad Hospital 40
Testing effectiveness (Phase 2)Study completedNCT04074746
What this trial is testing

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Who this might be right for
Recurrent Anaplastic Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Classic Hodgkin Lymphoma+7 more
M.D. Anderson Cancer Center 45
Early research (Phase 1)Study completedNCT00005813
What this trial is testing

Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme

Who this might be right for
Brain and Central Nervous System Tumors
Dartmouth-Hitchcock Medical Center
Early research (Phase 1)Looking for participantsNCT06095089
What this trial is testing

JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 355
Early research (Phase 1)WithdrawnNCT05950113
What this trial is testing

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
Early research (Phase 1)Looking for participantsNCT06515613
What this trial is testing

CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Who this might be right for
Platinum-resistant Ovarian CancerTesticular CancerEndometrial Cancer
Context Therapeutics Inc. 156
Early research (Phase 1)UnknownNCT05650385
What this trial is testing

B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

Who this might be right for
Neoplasms Malignant
Tasly Biopharmaceuticals Co., Ltd. 68
Testing effectiveness (Phase 2)Looking for participantsNCT07348055
What this trial is testing

GR1803 in Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus ErthematosusAuto Immune Disease
Genrix (Shanghai) Biopharmaceutical Co., Ltd. 44
Early research (Phase 1)Active Not RecruitingNCT06215118
What this trial is testing

Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Who this might be right for
Multiple Myeloma
Pfizer 100
Next Page